PDF下载 ( 1181 KB)
Therapeutic effect of antiviral therapy in chronic hepatitis B patients with nonalcoholic fatty liver disease
-
摘要:
目的对慢性乙型肝炎(CHB)合并非酒精性脂肪性肝病(NAFLD)患者抗病毒治疗疗效进行回顾性分析,探讨肝细胞脂肪变是否影响CHB患者抗病毒的疗效。方法收集2004年1月至2011年12月在本院进行抗病毒治疗的110例CHB患者,CHB合并NAFLD患者99例,采用荧光定量PCR法检测血清HBV DNA水平,用化学发光法检测血清乙型肝炎两对半定量,采用全自动生物化学分析仪检测肝功能。计数资料采用χ2检验,计量资料采用t检验。结果 (1)干扰素抗病毒治疗时,24周单纯CHB患者较合并脂肪肝患者生化学应答率更高(χ2=4.069,P=0.044);48周HBV DNA阴转率明显优于后者(χ2=17.327,P=0.000)。对于HBeAg阳性患者,单纯CHB患者在24周的生化学应答率、24和48周时的HBV DNA阴转率、HBeAg阴转率均显著优于合并脂肪肝患者,两者比较差异具有统计学意义(P<0.05),48周时两组的生化学应答差异无统计学意义(p>0.05)。(2)核苷和核苷酸类药物抗病毒治疗时,48周单纯CHB患者的生化学应答率较高(χ2=7.620,P=0.006),24...
Abstract:Objective To retrospectively analyze the therapeutic effect of antiviral therapy in the chronic hepatitis B (CHB) patients with nonalcoholic fatty liver disease (NAFLD) and to investigate whether hepatocyte steatosis affects the response to antiviral therapy in CHB patients.Methods A total of 110 CHB patients and 99 CHB patients with NAFLD were enrolled in the study.Serum HBV DNA levels were measured by fluorescence quantitative PCR;serum HBsAg, HBsAb, HBeAg, HBeAb, and HBcAb were quantified by chemiluminescence;biochemical indices were determined by automatic biochemical analyzer to evaluate the liver function.Results (1) When receiving antiviral therapy with interferon, the CHB patients had a significantly higher rate of alanine aminotransferase (ALT) /aspartate aminotransferase (AST) normalization after 24 weeks of treatment (χ2=4.069, P=0.044) and a significantly higher rate of HBV DNA clearance after 48 weeks of treatment (χ2=17.327, P=0.000) , as compared with the CHB patients with NAFLD;in all HBeAg-positive patients, those with only CHB had a significantly higher rate of ALT/AST normalization after 24 weeks of treatment (P<0.05) and significantly higher rates of HBV DNA clearance and HBeAg clearance after 24 and 48 weeks of treatment (P<0.05) 48="" as="" compared="" with="" those="" chb="" and="" but="" there="" was="" no="" significant="" difference="" in="" the="" rate="" of="" ast="" normalization="" between="" them="" after="" weeks="" treatment="" p="">0.05) . (2) When receiving antiviral therapy with nucleos (t) ide analogues, the CHB patients had a significantly higher rate of ALT/AST normalization than the CHB patients with NAFLD after 48 weeks of treatment (χ2=7.620, P=0.006) , but there was no significant difference in the rate of HBV DNA clearance between them after 24 and 48 weeks of treatment (P>0.05) ;in all HBeAg-positive patients, those with CHB and NAFLD had a significantly higher rate of HBeAg clearance after 24 weeks of treatment (P<0.05) and a significantly lower rate of ALT/AST normalization after 48 weeks of treatment (P<0.05) 24="" 48="" as="" compared="" with="" those="" only="" but="" there="" were="" no="" significant="" differences="" in="" the="" rate="" of="" ast="" normalization="" after="" weeks="" rates="" hbv="" dna="" clearance="" and="" hbeag="" treatment="" between="" them="" p="">0.05) .Conclusion To some extent, hepatocyte steatosis affects the response to antiviral therapy in CHB patients.
-
Key words:
- hepatitis B /
- chronic /
- fatty liver
-
[1]LIANG X, BI S, YANG W, et al.Epidemiological serosurvey of hepa-titis B in China-declining HBV prevalence due to hepatitis B vaccina-tion[J].Vaccine, 2009, 27 (47) :6550-6557. [2] FAN JG, FARRELL GC.Epidemiology of non-alcoholic fatty liverdisease in China[J].J Hepatol, 2009, 50 (1) :204-210. [3]Fatty Liver and Alcoholic Liver Disease Study Group of Chinese So-ciety of Hepatology.Guidelines for diagnosis and treatment of nonal-coholic fatty liver diseases[J].J Clin Hepatol, 2010, 26 (2) :120-124. (in Chinese) 中华医学会肝病学分会脂肪肝和酒精性肝病学组.非酒精性脂肪性肝病诊疗指南[J].临床肝胆病杂志, 2010, 26 (2) :120-124. [4]ZHENG RD, CHEN ZR, CHEN JN, et al.The correlation betweenbody mass index'waist-to-hip ratio'waist circumference chronichepatitis B with nonalcoholic fatty liver diseases[J/CD].Chin JExp Clin Infect Dis (Electronic Edition) , 2012, 6 (4) :312-315. (in Chinese) 郑瑞丹, 陈卓然, 陈建能, 等.体质量指数、腰臀比及腰围与慢性乙型肝炎并非酒精性脂肪性肝病的相关性研究[J/CD].中华实验和临床感染病杂志 (电子版) , 2012, 6 (4) :312-315. [5]ZHANG HF, ZHU SS.Current status and recent progress of antivi-ral treatment strategies for chronic hepatitis B in pediatric patients[J].J Clin Hepatol, 2012, 28 (12) :884-887. (in Chinese) 张鸿飞, 朱世殊.儿童慢性乙型肝炎抗病毒治疗现状[J].临床肝胆病杂志, 2012, 28 (12) :884-887. [6]ATES F, YALNIZ M, ALAN S.Impact of liver steatosis on re-sponse to pegylated interferon therapy in patients with chronic hepa-titis B[J].World J Gastroenterol, 2011, 17 (40) :4517-4522. [7] SHI JP, LU L, QIAN JC, et al.Impact of liver steatosis on antiviraleffects of pegylated interferon-alpha in patients with chronic hepa-titis B[J].Chin J Hepatol, 2012, 20 (4) :285-288. (in Chi-nese) 施军平, 陆璐, 钱建成, 等.肝脂肪变对慢性乙型肝炎患者聚乙二醇干扰素α治疗临床疗效的影响[J].中华肝脏病杂志, 2012, 20 (4) :285-288. [8]JIN X, CHEN YP, YANG YD, et al.Association between hepatic steato-sis and entecavir treatment failure in chinese patients with chronic hepati-tis B[J].PLoS one, 2012, 7 (3) :e34198. 期刊类型引用(6)
1. 张明. 酒精性肝病合并乙型肝炎病毒感染病例临床分析. 中国医药指南. 2024(02): 114-116 . 
百度学术2. 吴琦玮，高杨，李艳辉，沈榕. 2015—2019年北京地区乙型肝炎疾病负担及趋势预测分析. 实用预防医学. 2024(11): 1349-1352 . 百度学术3. 董丹丹，邱利，胡毅. 慢性HBV感染合并非酒精性脂肪性肝病患者血清脂联素、ROS及糖脂代谢特征. 肝脏. 2024(10): 1265-1268+1273 . 百度学术4. 毛垚耀，何惠昌，谢露，崔健娇，刘光伟. 健脾活血解毒方联合恩替卡韦对乙型病毒性肝炎合并非酒精性脂肪性肝病小鼠的干预作用及机制. 现代中西医结合杂志. 2023(08): 1047-1052 . 百度学术5. 沈从乐，李韦杰，任博，孙继云，王雅杰. 2543例不同病因慢性肝病糖脂代谢异常率分析. 标记免疫分析与临床. 2022(09): 1451-1454 . 百度学术6. 倪盟，曾雷. miRNA单核苷酸多态性与HBV感染相关疾病关系的研究进展. 吉林大学学报(医学版). 2021(06): 1588-1593 . 百度学术其他类型引用(1)
-
百度学术
下载:
